Scope
The joint European Society of Endocrinology and Endocrine Society guideline addresses glucocorticoid-induced adrenal insufficiency during treatment, tapering and recovery, together with stress coverage and adrenal crisis. Its recommendations distinguish control of the underlying disease from recovery of the hypothalamic–pituitary–adrenal axis.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Education and exposure-related risk
- Educate patients about the endocrine implications of glucocorticoid treatment and ensure access to current, appropriate information. Routine endocrinology assessment is generally unnecessary merely because glucocorticoids are being used or tapered for a non-endocrine condition. [1]
- For oral glucocorticoid exposure, the source identifies risk when duration reaches at least 3–4 weeks and the dose exceeds the physiologic daily hydrocortisone equivalent of 15–25 mg, corresponding to 4–6 mg prednisone or prednisolone. Both dose and duration matter. [1]
When and how to taper
- For short-term treatment lasting <3–4 weeks, the guideline suggests stopping without tapering or adrenal testing, irrespective of dose, because concern about HPA suppression is low. [1]
- Attempt tapering after long-term treatment only when the underlying disease is controlled and glucocorticoids are no longer needed. Taper towards a physiologic daily equivalent, for example prednisone 4–6 mg. [1]
- Consider glucocorticoid withdrawal syndrome during tapering. If symptoms are severe, the dose can temporarily return to the most recently tolerated level and the taper can be extended. [1]
- Do not routinely test adrenal function while doses remain supraphysiologic or glucocorticoids are still needed for the underlying illness. When a long-acting drug is no longer needed, the guideline suggests switching to a shorter-acting option such as hydrocortisone or prednisone. [1]
- At a physiologic daily dose, a patient aiming to stop may either continue a gradual taper with clinical monitoring for adrenal insufficiency or have morning serum cortisol measured. [1]
Assess recovery using morning cortisol
- If biochemical confirmation of HPA recovery is desired, morning serum cortisol is the first test. Interpret it as a continuum: higher values make recovery more likely, rather than treating the thresholds as context-free guarantees. [1]
- As a guide, cortisol >300 nmol/L or 10 μg/dL suggests HPA recovery and permits stopping glucocorticoids. This interpretation belongs to the assessment of recovery during discontinuation. [1]
- For morning cortisol between 150 nmol/L or 5 μg/dL and 300 nmol/L or 10 μg/dL, continue the physiologic glucocorticoid dose and repeat testing after an appropriate interval, usually weeks to months. [1]
- If morning cortisol is <150 nmol/L or 5 μg/dL, continue the physiologic dose and repeat morning cortisol after a few months. [1]
- The guideline suggests against routine dynamic adrenal testing in people tapering or stopping glucocorticoids. [1]
Other exposures and specialist review
- Consider possible adrenal insufficiency with symptoms after recent or current non-oral glucocorticoids, simultaneous multiple formulations, high-dose inhaled or topical use, or inhaled or topical treatment for >1 year. [1]
- Recent intra-articular injections within 2 months and co-treatment with strong cytochrome P450 3A4 inhibitors are additional circumstances in which the guideline suggests awareness of adrenal insufficiency. [1]
- Assume glucocorticoid-induced adrenal insufficiency when current or previous glucocorticoid treatment is accompanied by signs and symptoms of exogenous Cushing syndrome. [1]
- Seek endocrinology assessment when HPA recovery has not occurred after one year on a physiologic equivalent while attempting discontinuation, or when there is a history of adrenal crisis. Fludrocortisone is not recommended for glucocorticoid-induced adrenal insufficiency. [1]
Stress coverage and suspected crisis
- People with current or recent glucocorticoid exposure who have not had biochemical testing to exclude adrenal insufficiency should receive glucocorticoid stress coverage when exposed to stress. [1]
- For these untested patients, oral glucocorticoids are used for minor stress when there is no haemodynamic instability or prolonged vomiting or diarrhoea. [1]
- For these untested patients, use parenteral glucocorticoids for moderate or major stress, procedures under general or regional anaesthesia, prolonged inability or avoidance of oral intake, haemodynamic instability, or prolonged vomiting or diarrhoea. [1]
- Consider adrenal crisis in an untested patient with current or recent glucocorticoid use who develops haemodynamic instability, vomiting or diarrhoea, regardless of drug type, route or dose. Treat suspected crisis with parenteral glucocorticoids and fluid resuscitation. [1]
Limitations and use
- This summary covers the society’s published recommendation list, not the full evidence rationale or every taper and stress-dose schedule.
- Specific stress-dose and emergency replacement regimens are not supplied here; cortisol thresholds are a guide within the clinical recovery assessment.
- These recommendations concern glucocorticoid-induced adrenal insufficiency, not all causes of primary or secondary adrenal failure.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Glucocorticoid-induced adrenal insufficiency
Selected recommendation material consulted
Publication details
- Issuing organisation
- ESE / Endocrine Society
- First published
- 13 May 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.